An analytical framework for immunization programs in Canada

Vaccine

Volumn 23, Issue 19, 2005, Pages 2470-2476

  Erickson, L J ^a,b   De Wals, P ^c,d   Farand, L ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Gouvernement du Quebec   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Immunization; Public health; Vaccine

Indexed keywords

CHICKENPOX VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE;

ANALYTIC METHOD; ARTICLE; AWARENESS; CANADA; CHICKENPOX; CONSENSUS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEASIBILITY STUDY; HEALTH CARE PLANNING; HEALTH EDUCATION; HEALTH PRACTITIONER; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNIZATION; INTERMETHOD COMPARISON; LEGAL ASPECT; MEASLES; MEDICAL ETHICS; MEDICAL RESEARCH; MENINGITIS; POLITICS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; HEALTH CARE POLICY; HEALTH SERVICES RESEARCH; METHODOLOGY;

CANADA; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; IMMUNIZATION PROGRAMS;

EID: 14744291422     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.10.029     Document Type: Article

References (42)

1. Canadian Immunization Guide. sixth ed. Ottawa: Centre for Infectious Disease Prevention and Control, Health Canada; 2002.
2. Canadian Task Force on the Periodic Health Examination. The Canadian guide to clinical preventive health care. Ottawa: Minister of Supply and Services Canada; 1994.
3. Committee to Advise on tropical Medicine and travel. http://www.hc-sc.gc. ca/pphb-dgspsp/tmp-pmv/catmat-ccmtmv/about_e.html.
4. P. De Wals, B. Duval, G. De Serres, N. Boulianne, and M. Dionne Santé publique: le contrôle des maladies méningococciques au Québec Med Sci 19 2003 1011 1015
5. B. Sibbald One country, 13 immunization programs CMAJ 168 2003 598
6. N. MacDonald, and J. Embree Access to vaccines: A call to action Can J Infect Dis 14 2003 9 10
7. M. Naus, and D.W. Scheifele Canada needs a national immunization program: an open letter to the Honourable Anne McLellan, Federal Minister of Health CMAJ 168 2003 567 568
8. M.M. Levine, and O.S. Levine Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use Lancet 350 1997 1386 1392
9. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century: a tool for decision-making. Committee to Study Priorities for Vaccine Development. Division of Health Promotion and Disease Prevention. Institute of Medicine. Washington, DC: National Academy Press; 1999.
10. White FMM, and R.G. Mathias Immunization program planning in Canada Can J Public Health 73 1982 167 171
11. B. Law, C. Fitzsimon, L. Ford-Jones, N. MacDonald, P. Dery, and W. Vaudry Cost of chickenpox in Canada: Part I. Cost of uncomplicated cases Pediatrics 104 1999 1 6
12. B. Law, C. Fitzsimon, L. Ford-Jones, J. McCormick, and M. Riviere Cost of chickenpox in Canada: Part II. Cost of complicated cases and total economic impact Pediatrics 104 1999 7 14
13. P. De Wals, M. Blackburn, M. Guay, G. Bravo, D. Blanchette, and M. Douville-Fradet Burden of chickenpox on families: a study in Quebec Can J Infect Dis 12 2001 27 32
14. D. Scheifele, S. Halperin, L. Pelletier, J. Talbot and Members of the Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT) Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies Clin Infect Dis 31 2000 58 64
15. G. Petit, P. De Wals, B. Law, T. Tam, L.J. Erickson, and M. Guay Epidemiological and economic burden of pneumococcal disease in Canadian children Can J Infect Dis 14 2003 215 220
16. P. De Wals, V.H. Nguyen, L.J. Erickson, M. Guay, J. Drapeau, and J. St-Laurent Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease Vaccine 22 2004 1233 1240
17. L.D. Senzilet, S.A. Halperin, J.S. Spika, M. Alagaratnam, A. Morris, and B. Smith Pertussis is a frequent cause of prolonged cough illness in adults and adolescents Clin Infect Dis 2001 2001 1691 1697
18. D.M. Skowronski, G. De Serres, D. MacDonald, W. Wu, C. Shaw, and J. Macnabb The changing age and seasonal profile of pertussis in Canada J Infect Dis 185 2002 1448 1453
19. G. De Serres, R. Shadmani, B. Duval, N. Boulianne, P. Dery, and M. Douville-Fradet Morbidity of pertussis in adolescents and adults J Infect Dis 182 2000 174 179
20. National Advisory Committee on Immunization (NACI). Statement on pertussis vaccine. CCDR 1997; 23(ACS-3):1-16.
21. R.E. Schabas Mass influenza vaccination in Ontario: a sensible move JAMC 164 2001 36 37
22. A. Yassi, J. Kettner, G. Hammond, M. Cheang, and M. McGill Effectiveness and cost-benefit of an influenza vaccination program for health care workers Can J Infect Dis 2 1991 101 108
23. L. Pelletier, P. Chung, P. Duclos, P. Manga, and J. Scott A benefit-cost analysis of two-dose measles immunization in Canada Vaccine 16 1998 989 996
24. P. De Wals, M. Guay, J. Drapeau, C. St-Hilaire, R. Hébert, and J. Pépin Pneumococcal immunization program: cost-utility analysis for Quebec Can J Infect Dis 10 Suppl. A 1999 46A 47A
25. M. Brisson, and W.J. Edmunds The cost-effectiveness of varicella vaccination in Canada Vaccine 20 2002 1113 1125
26. D. Getsios, J.J. Caro, G. Caro, P. De Wals, B.J. Law, and Y. Robert Instituting a routine varicella vaccination program in Canada: an economic evaluation Pediatr Infect Dis J 21 2002 542 547
27. M.H. Lebel, J.D. Kellner, E.L. Ford-Jones, K. Hvidsten, E.L. Wang, and V. Ciuryla A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada Clin Infect Dis 36 2003 259 268
28. P. De Wals, G. Petit, L.J. Erickson, M. Guay, T. Tam, and B. Law Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada Vaccine 21 2003 3757 3764
29. D. Moore, M. Bigham, and D. Patrick Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia Can Commun Dis Rep 29 2003 97 104
30. T.O. Tengs, M.E. Adams, J.S. Pliskin, D.G. Safran, J.E. Siegel, and M.C. Weinstein Five-hundred life-saving interventions and their cost-effectiveness Risk Anal 15 1995 369 390
31. P.W. Stone, S. Teutsch, R.H. Chapman, C. Bell, S.J. Goldie, and P.J. Neumann Cost-utility analyses of clinical preventive services. Published ratios Am J Prevent Med 19 2000 15 23
32. P. De Wals, M.A. Allard, K. Guindon, L. Mayrand, S. Simard, and R. Black Is vaccination against meningitis useful? The findings of an investigation in the Sherbrooke region CCDR 28 2002 61 63
33. National Advisory Committee on Immunization (NACI). Statement on recommended use of meningococcal vaccines. CCDR 2001; 27(ACS-6):2-36.
34. M. Brisson, W.J. Edmunds, and N.J. Gay Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV J Med Virol 70 Suppl. 1 2003 S31 S37
35. Proceedings of the National Varicella Consensus Conference. CCDR Suppl 1999; 25S5, Montreal, Quebec.
36. B. Mackay Paramedics face dismissal for refusing flu shots CMAJ 166 2002 796
37. S. Iwarson Are we giving too many doses of hepatitis A and B vaccines? Vaccine 20 2002 2017 2018
38. W.J. Edmunds, and M. Brisson The effect of vaccination on the epidemiology of varicella zoster virus J Infect 44 2002 211 219
39. J. Greene To be or not to be vaccinated. The smallpox controversy plays out in California hospitals Trustee 56 2003 14 71
40. Comité sur l'immunisation du Québec. Rapport sur l'utilisation d'un vaccin contre la varicelle au Québec. Québec: Institut national de santé publique du Québec; 2000.
41. Groupe de travail sur le vaccin antipneumococcique conjugué. Utilisation du vaccin antipneumococcique conjugué au Québec. Québec: Institut national de santé publique du Québec; 2003.
42. Comité sur l'immunisation du Québec. Pertinence de l'introduction du vaccin méningococcique dans le calendrier régulier d'immunisation au Québec. Québec: Institut national de santé publique du Québec; 2002.